Based on: Hypertension — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 8 October 2026; the tracker page is the live version.
Short answer: as of October 2026, the OSMF Research Tracker lists 53 candidate interventions for hypertension that are either approved medicines or have at least one registered clinical trial, built on 13 druggable gene targets, with 15 recent trials on ClinicalTrials.gov. 6 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- Azilsartan — 2 registered trials · approved medicine · NCT02079805 NCT02100319
- sibutramine — 2 registered trials · investigational · NCT00679653
- Chlorthalidone — 1 registered trial · approved medicine · NCT00241839
- cilnidipine — 1 registered trial · approved medicine · NCT00325637
- Labetalol — 1 registered trial · approved medicine · NCT01912677
- Methyldopa — 1 registered trial · approved medicine · NCT01912677
- Telmisartan — 1 registered trial · approved medicine · NCT02079805
- 1 dose of Beetroot juice intake — 1 registered trial · investigational · NCT06584331
- 2 doses of Beetroot juice intake — 1 registered trial · investigational · NCT06584331
- 24-hour ambulatory blood pressure monitor — 1 registered trial · investigational · NCT05866445
- AGV implantation — 1 registered trial · investigational · NCT00628173
- Ali/Amlo 150/2.5 mg — 1 registered trial · investigational · NCT01237873
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in hypertension and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: ACE, ADRB1, ADRB2, AGT, AGTR1, AGTR2, CACNA1C, EDN1, NOS3, NPR1, NR3C2, REN, SLC12A3.
Which trials are registered?
- Endothelial Cell Dysfunction in Pulmonary Hypertension NCT00098072 · Completed · Phase PHASE1 · started 2000-05-17
- Natural History of Sickle Cell Disease NCT00081523 · Recruiting · started 2004-04-29
- DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia NCT07623525 · Recruiting · Phase PHASE1, PHASE2 · started 2026-06-04
- Aerobic Exercise in Patients With Pulmonary Hypertension NCT00678821 · Completed · Phase PHASE2 · started 2008-06-12
- Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension NCT06911632 · Recruiting · Phase NA · started 2025-07-23
- Impact of Exercise Prescription on Obstetric and Neonatal Outcomes NCT07678944 · Completed · Phase NA · started 2024-02-01
- Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects NCT04401982 · Recruiting · Phase PHASE4 · started 2026-07-02
- Natural History Study of Biomarkers in Pulmonary Arterial Hypertension NCT01730092 · Recruiting · started 2013-07-15
- Ocular Blood Flow Imaging for Glaucoma Assessment NCT05726058 · Recruiting · Phase NA · started 2023-03-30
- WS-SAVE Study (Williams Syndrome Skin and Vessel Elasticity Study) NCT02692846 · Completed · started 2017-03-03
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take.
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 8 October 2026.